BioSpace News Archive

Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced a late-breaker presentation at the 2020 Multidisciplinary Head and Neck Cancers Symposium, which is taking place February 27-29, 2020, in Scottsdale, Ariz.

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to provide additional information on the drug development program for QIXLEEF™ following the previously announced Letter of Advice and Type B meeting with the US Food and Drug Administration (FDA).

LAKE FOREST, California , Feb. 24, 2020 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD ) (“InMode”), a leading global provider of innovative medical technologies, has received Health Canada certification for Evoke, a breakthrough aesthetic solution for treating wrinkles and rhytids. Evoke is the first and only hands-free device designed

NEW YORK , Feb. 24, 2020 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the launch of its digital therapeutics solution for managing chronic diseases such as diabetes and hypertension on Albertsons Marketplace . Albertsons Companies is one of the largest reta

ICER adopts Aetion’s real-world evidence platform - advancing standards for the use of transparent, replicable real-world evidence in health technology assessment

Renovacor, Inc, a preclinical-stage biopharmaceutical company focused on developing transformative gene therapy-based treatments for cardiovascular disease, today announced the addition of Dr. Anne Prener to both the company’s board of directors and scientific advisory board.

Feb. 24, 2020 13:00 UTC FDA Grants Premarket Clearance of Asuragen’s AmplideX ® Fragile X Dx and Carrier Screen Kit The first IVD for the diagnosis and screening of fragile X syndrome and other FMR1-related disorders AUSTIN, Texas--( BUSINESS WIRE )-- Asuragen, Inc. , a molecular diagnostics company delivering high-quality, easy-to-use products for complex testing in genetics and oncology, today announced that its AmplideX ® Fragile X Dx and Carrier Screen Kit has been c

Feb. 24, 2020 13:00 UTC Noveome Biotherapeutics, Inc. to Present at the 8 th Annual Neurodegenerative Drug Development Summit PITTSBURGH--( BUSINESS WIRE )-- Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, today announced that Larry Brown, Sc.D., Executive Vice President and Chief Scientific Officer at Noveome, will prese

Feb. 24, 2020 13:30 UTC Zymeworks to Present at Raymond James 41 st Annual Institutional Investors Conference VANCOUVER, British Columbia--( BUSINESS WIRE )-- Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Raymond James Institutional Investors Conference taking place March 1-4, 2020 in Orlando, FL. The Company’s presentation will be on Monday, March 2

Feb. 24, 2020 13:30 UTC – MGTA-117 ADC clinical candidate for conditioning showed broad tolerability and wide pre-clinical safety margins – – MGTA-117 demonstrated robust anti-tumor activity in xenograft models from patients with refractory leukemia – – Magenta plans to move MGTA-117 into the clinic with initial clinical data in 2021 – – Landmark data with tool CD117-ADC demonstrate first successful gene therapy transplant without chemotherapy in non-human primates, awar